Filtreler
Filtreler
Bulunan: 10 Adet 0.001 sn
Koleksiyon [7]
Tam Metin [1]
Yayın Türü [2]
Yazar [20]
Yayın Yılı [5]
Konu Başlıkları [20]
Yayıncı [7]
Yayın Dili [2]
Dergi Adı [8]
Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology)

Süner A. | Aydin D. | Hacioglu M.B. | Dogu G.G. | Imamoglu G.I. | Menekşe S. | Pilanci K.N.

Article | 2016 | European Review for Medical and Pharmacological Sciences20 ( 7 ) , pp.1238 - 1243

OBJECTIVE: Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, docetaxel has been used as standard treatment for years. Cabazitaxel has become the first chemotherapeutic agent which has been shown to increase survival for patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) that progresses after docetaxel. Phase 3 TROPIC study demonstrated that cabazitaxel prolongs survival. PATIENTS AND METHODS: In this study, we evaluated a total of 103 patients who took cabaz . . .-itaxel chemotherapy for mCRPC diagnosis in 21 centers of Turkey, retrospectively. This study included patients who progressed despite doc-etaxel treatments, had ECOG performance score between 0-2, and used cabazitaxel treatment. Patients received cabazitaxel 25 mg/m2 at every 3 weeks, and prednisolone 5 mg twice a day. RESULTS: Median number of cabazitaxel cures was 5.03 (range: 1-17). Cabazitaxel response evaluation detected that 34% of the patients had a partial response, 22.3% had stable disease and 32% had a progressive disease. Grade 3-4 hema-tological toxicities were neutropenia (28.2%), neutropenic fever (14.5%), anemia (6.7%), and thrombocytopenia (3.8%). In our study, median progression-free survival (PFS) was 7.7 months and overall survival (OS) was 10.6 months. CONCLUSIONS: This study reflects toxicity profile of Turkish patients as a Caucasian race. We suggest that cabazitaxel is a safe and effective treatment option for mCRPC patients who progress after docetaxel. Moreover, ethnicity may play important roles both in treatment response and in toxicity profile Daha fazlası Daha az

A multiscale model for acid-mediated tumor invasion: Therapy approaches

Meral, Gulnihal | Stinner, Christian | Surulescu, Christina

Article | 2015 | JOURNAL OF COUPLED SYSTEMS AND MULTISCALE DYNAMICS3 ( 2 ) , pp.135 - 142

Starting from the two-scale model for pH-taxis of cancer cells introduced previously by the authors, we consider here an extension accounting for tumor heterogeneity w.r.t. treatment sensitivity and a treatment approach including chemo-and radiotherapy. The effect of peritumoral region alkalinization on such therapeutic combination is investigated with the aid of numerical simulations.

Dental management long term follow-up of the post radio-chemotherapy-Rhabdomyosarcoma patient: Report of a case

Misir A.F. | Zerener T. | Günhan T.

Article | 2014 | Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology26 ( 2 ) , pp.154 - 157

Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood and adolescence involving the head and neck. It occurs most often in the head and neck region, genitourinary tract, retroperitoneum and the extremities. The current treatment of a combination of surgery, chemotherapy and radiotherapy has dramatically improved the long term survival rates over the last 20 years. However, some of the side effects of post-radiation include delayed eruption of teeth, retarded tooth and bone development, dwarfed teeth, partial anadontia, osteoradionecrosis, xerostomia, mucositis, candidiasis, trismus, loss of taste, soft tissue ne . . .crosis, and scar tissue formation. RMS is a comparatively rare lesion for the maxillofacial surgeons. Although documented to be the most common soft tissue sarcoma in children under 15 years of age, there is, however, a paucity of reports on the pattern of the late effects of multimodal treatment results about intra-oral involvement. This case report focused on the dental treatment and facial abnormalities in a long-term survivor of pediatric head and neck RMS patient and review of the literature. © 2012 Daha fazlası Daha az

Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer

Ozaslan E. | Topaloglu U.S. | Inanc M. | Erdem U.G. | Demir H. | Arpaci E. | Seker M.M.

Review | 2017 | Journal of B.U.ON.22 ( 4 ) , pp.863 - 868

Purpose: To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients. Methods: IPatients were administered cetuximab plus FOLFOX as second- and third-line therapy from January 2010 through October 2015. mCRC patients with wild type KRAS were als? given irin?tecan and/?r ?xaliplatin c?mbined with fluor?pyrimidine±bevacizumab. Tumor resp?nse and survival were evaluated using RECIST and Kaplan-Meier meth?d respectively. Results: Sixty patients were included this study. Cetuximab plus FOLFOX was administered to 40 (66.7%) patients a . . .s second-line and to 20 (33.3%) as third-line therapy. The majority of the patients had a good ECOG performance status (PS) (0 or 1). Clinical benefit was partial plus stable disease and it was 75.0% for both of these two lines. The median progression free survival (PFS) was 7.1 months (95% CI=3.2-10.9) and 6.0 months (95% CI=2.4-9.6), in the second- and third-line (p=0.484). The median ?verall survival (?S) was 14.3 and 9.2 m?nths in sec?nd- and third-line therapy respectively (p=0.071). The common toxicities were haematologic and gastrointestinal, mostly grade 1 and 2. Conclusion: The addition of cetuximab to FOLFOX was well-tolerated and had antitumor activity both in second- and third-line therapy in patients with mCRC. © 2017 Zerbinis Publications. All rights reserved Daha fazlası Daha az

Chemotherapy extravasation results in skin necrosis and cellulitis: A case report [Kemoterapi ekstravazasyonuna bağlı deri nekrozu ve selülit: Bir olgu sunumu]

Gülüş Demirel B. | Koca R. | Solak Tekin N.

Article | 2015 | Turk Onkoloji Dergisi30 ( 3 ) , pp.144 - 147

Extravasation, the accidental leakage of an anticancer agent from a vessel into the surrounding tissues, can lead to irreversible local injuries and severe disability. Altough several oral chemotherapy agents have been developed, most chemotherapy agents are administered intravenously. The extravasation of cancer chemotherapeutic agents can easily occur and may cause severe and irreversible local injuries. The incidence of extravasation of chemotherapeutic agents has been reported to ocur in 0.01–6.9% of cases. Extravasated drugs are classified according to their potential for causing damage as vesicant, irritant and nonvesicant. In . . . this report we represent a multipl myeloma patient who has skin necrosis and cellulitis after chemotherapy infusion. © 2015 Turkish Society for Radiation Oncology Daha fazlası Daha az

Effects of folinic acid and fluorouracil chemotherapy on right ventricle functions as assessed with tricuspid annular plane systolic excursion

Bilir C. | Engin H. | Karabag T. | Colak D.

Article | 2014 | Hippokratia18 ( 4 ) , pp.346 - 349

Aim: This study aimed to investigate the effects of folinic acid and fluorouracil (bolus FUFA regimen) chemotherapy on right ventricle (RV) functions. Materials and Methods: Thirty-four gastrointestinal (GI) cancer patients treated with antineoplastic drugs were included the study. All participants received FUFA chemotherapy protocol for colorectal, gastric and pancreatic cancer (i.e. fluorouracil 400-425 mg/m2 intravenous day 1-5 + folinic acid 20-25 mg/m2 intravenous day 1-5 every 28 days x6 cycles) with or without radiation therapy according to the cancer and patient status. All participants have undergone complete physical and l . . .aboratory examination and complete echocardiographic evaluation including detailed right ventricle functional evaluations before the onset of chemotherapy and 6 months after the start of treatment. Results: Mean RV thickness was 0.49 cm before chemotherapy and 0.62 cm at the end of the treatment (p=0.29). Mean tricuspid annular plane systolic excursion (TAPSE) values were 2.08 ± 0.3 and 2.00 ± 0.39 cm, respectively (p=0.25). RV total ejection isovolumic (Tei) index related to the chemotherapy did not change significantly (0.24 and 0.29, respectively, p=0.07). Also we did not find significant chance in the RV end diastolic diameter, RV end systolic diameter, vena cava diameter on inspiration and expiration. Conclusion: Bolus FUFA regimen chemotherapy does not diminish the RV functions as assessed by TAPSE and RV Tei index in GI cancer patients. © 2014, Hippokratia General Hospital of Thessaloniki. All rights reserved Daha fazlası Daha az

Radiation therapy for biliary tract tumors: The joint experience of three centers

Karabey M.S. | Yirmibeşoğlu Erkal E. | Yolcu A. | Bakkal, Bekir Hakan | Ay Ö. | Aksu M.G. | Sarper E.B.

Article | 2017 | Turkish Journal of Medical Sciences47 ( 2 ) , pp.412 - 416

Background/aim: This study presents the joint experience of three centers in the treatment of patients with biliary tract tumors with radiation therapy (RT). Materials and methods: The records of 27 patients were retrospectively reviewed. All of the patients who had undergone surgical resection received postoperative adjuvant RT, whereas all of the patients who had not undergone a surgical resection received RT with palliative intent. Twenty patients with adequate performance status were treated with RT and chemotherapy, while the remaining seven patients were treated with RT alone. Results: Follow-up ranged from 1 to 44 months. Loc . . .al control was not achieved in 10 out of 11 patients who had received RT with palliative intent. Systemic failure was observed in eight patients at 5 to 16 months. Fifteen patients died due to disease-related causes at 1 to 22 months. At 2 years, overall survival was 33% and disease-free survival was 19%. A surgical resection with curative intent predicted improved local failure-free survival and improved disease-free survival. Conclusion: Since local recurrence is still the leading cause of failure following postoperative RT and the outcome following palliative RT is far from satisfactory, the indications, the target volume, and the doses for RT should be reconsidered. © TÜBİTAK Daha fazlası Daha az

Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: Report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO)

Aydin D. | Sendur M.A. | Kefeli U. | Unal O.U. | Tastekin D. | Akyol M. | Tanrikulu E.

Article | 2016 | Journal of B.U.ON.21 ( 5 ) , pp.1242 - 1249

Purpose: Small bowel adenocarcinoma (SBA) is a rare tumor of the gastrointestinal system with poor prognosis. Since these are rarely encountered tumors, there are limited numbers of studies investigating systemic treatment in advanced SBA. The purpose of this study was to evaluate the prognostic factors and systemic treatments in patients with advance SBA. Methods; Seventy-one patients from 18 Centers with advanced SBA were included in the study. Fifty-six patients received one of the four different chemotherapy regimens as first-line therapy and 15 patients were treated with best supportive care (BSC). Results: Of the 71 patients, . . .42 (59%) were male and 29 (41%) female with a median age of 56 years. Median follow-up duration was 14.3 months. The median progression free survival (PFS) and overall survival (OS) were 7 and 13 months, respectively (N=71). In patients treated with FOLFOX (N=18), FOLFIRI (N=ll), cisplatin-5-fluoroura-cil/5-FU (N=17) and gemcitabine alone (N=10), median PFS was 7, 8, 8 and 5 months, respectively; while median OS was 15, 16,15 and 11 months, respectively. No significant differences between chemotherapy groups were noticed in terms of PFS and OS. Univariate analysis revealed that chemotherapy administration, de novo metastatic disease, ECOG PS 0 and 1, and overall response to therapy were significantly related to improved outcome. Only overall response to treatment was found to be significantly prognostic in multivariate analysis (p= 0.001). Conclusions: In this study, overall response to chemotherapy emerged as the single significant prognostic factor for advanced SBAs. Platin and irinotecan based regimens achieved similar survival outcomes in advanced SBA patients Daha fazlası Daha az

The influence of cisplatin, doxorubicin, pegylated doxorubicin, oxaliplatin and gemcitabine on mahlavu cell line

Ilikhan S.U. | Bilici M. | Sahin H. | Akca A.S.D. | Engin H. | Bilir C. | Sevinc N.

Article | 2015 | Journal of B.U.ON.20 ( 2 ) , pp.608 - 613

Purpose: Hepatocellar carcinoma (HCC) remains a major health problem being the third leading cause of deaths due to cancer worldwide. Because HCC is known to be highly resistant to conventional systemic therapies, single-agent or combination of systemic therapies have been investigated Today, sorafenib, a multikinase inhibitor, is the only approved systemic agent for the first line treatment of advanced HCC. In this study, we aimed to investigate the influence of different concentrations of cisplatin, doxorubicin, pegylated doxorubicin (PLD), oxaliplatin and gemcitabine by applying these agents either single or in combinations on ma . . .hlavu cell line. Methods: HCC mahlavu cell line was used for the experiments. Cell death was measured by flow cytometry at 48 hrs after incubation with various concentrations (0.1 uglml, 1.0 uglml and 10 uglml) of the drugs. Results: Cell death due to gemcitabine was found to be significantly higher than cell deaths caused by the other single agents including cisplatin, oxaliplatin, doxorubicin and PLD ( Daha fazlası Daha az

Chemotherapy in elderly patients with metastatic gastric cancer; a single Turkish cancer center experience

Bilir C. | Engin H. | Bakkal, Bekir Hakan | Ilikhan S.U. | Malkoç D.

Article | 2013 | Medicinski Glasnik10 ( 2 ) , pp.298 - 303

Aim To analyze the results of chemotherapy applied at the Bülent Ecevit University School of Medicine, Department of Medical Oncology, to elderly patients with metastatic gastric cancer (GC). Methods The study retrospectively investigated hospital records including pathological reports, imaging records, chemotherapy regimens, response and toxicity profile. All patients received systemic chemotherapy for pathologically proven metastatic GC at the Bülent Ecevit University School of Medicine, Department of Medical Oncology. Results From 2005 to 2012, 23 metastatic GC patients older than 70 years were treated with systemic chemotherapy . . .as a first-line therapy. As the first-line chemotherapy, 17 (74%) patients received polychemotherapy and the remaining six (26%) patients received monotherapy. Overall, 113 cycles were administered. The median progression free survival (PFS) for the first-line chemotherapy was 6 months (95% CI, 0-16) and the median overall survival (OS) was 14 months (95% CI, 3-30). Multivariate analysis revealed that decreased OS was significantly associated with poor Eastern Cooperative Oncology Group (ECOG) performance status (p=0.045), elevated carcinoembryonic antigen (CEA) levels at the diagnosis time (p = 0.040) and decreased number of chemotherapy cycles (p=0.019) with R-Sq (adj) = 41, 6%. One patient had a complete response with docetaxel, cisplatin and fluorouracil combined (DCF) regimen and had 12 months of disease free survival (DFS). Conclusion This is the first study investigating the outcomes of chemotherapy in Turkish elderly metastatic GC patients. Docetaxel, cisplatin and fluorouracil combination were the most common regimen, which is a tolerable and effective choice in elderly patients who had good performance status Daha fazlası Daha az

6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms